AR004961A1 - Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el - Google Patents
Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para elInfo
- Publication number
- AR004961A1 AR004961A1 ARP960104981A ARP960104981A AR004961A1 AR 004961 A1 AR004961 A1 AR 004961A1 AR P960104981 A ARP960104981 A AR P960104981A AR P960104981 A ARP960104981 A AR P960104981A AR 004961 A1 AR004961 A1 AR 004961A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- medicines
- chroman
- oxo
- butyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 230000004048 modification Effects 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La invencion se refiere a la modificacion cristalina V del clorhidrato del compuesto (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)--butil]-aminometil}-cromano, de formula (I) que es estable a temperatua ambiente. La modificacion cristalina V del clorhidrato es apropiadaespecialmente para la preparacion de medicamentos solidos, especialmente de medicamentos para el tratamiento de la degeneraciones neuronales. La invencionse refiere ademas al procedimiento para preparar dicho clorhidrato, medicamentos que lo contienen, el uso del mismo para preparar dichosmedicamentos, una composicion para el tratamiento y prevencion de degeneraciones neuronales debidas a eventos isquemicos y un metodo para tratary prevenir dichas degeneraciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19543478A DE19543478A1 (de) | 1995-11-22 | 1995-11-22 | Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004961A1 true AR004961A1 (es) | 1999-04-07 |
Family
ID=7778081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104981A AR004961A1 (es) | 1995-11-22 | 1996-10-30 | Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5830908A (es) |
| EP (1) | EP0775704B1 (es) |
| JP (1) | JPH09143180A (es) |
| KR (1) | KR970027079A (es) |
| CN (1) | CN1086703C (es) |
| AR (1) | AR004961A1 (es) |
| AT (1) | ATE201872T1 (es) |
| AU (1) | AU712922B2 (es) |
| BR (1) | BR9605646A (es) |
| CA (1) | CA2190700A1 (es) |
| CZ (1) | CZ289730B6 (es) |
| DE (2) | DE19543478A1 (es) |
| DK (1) | DK0775704T3 (es) |
| EE (1) | EE9600183A (es) |
| ES (1) | ES2159342T3 (es) |
| GR (1) | GR3036505T3 (es) |
| HU (1) | HUP9603237A3 (es) |
| IL (1) | IL119647A (es) |
| MX (1) | MX9605741A (es) |
| MY (1) | MY132473A (es) |
| NO (1) | NO307340B1 (es) |
| NZ (1) | NZ299780A (es) |
| PL (1) | PL317090A1 (es) |
| PT (1) | PT775704E (es) |
| RU (1) | RU2181723C2 (es) |
| SG (1) | SG44989A1 (es) |
| SI (1) | SI0775704T1 (es) |
| SK (1) | SK150096A3 (es) |
| TR (1) | TR199600930A2 (es) |
| TW (1) | TW449595B (es) |
| UA (1) | UA45338C2 (es) |
| ZA (1) | ZA969753B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854217A (en) * | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP3542801A1 (en) * | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purin derivatives for use in the treatment of fap-related diseases |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR101657960B1 (ko) * | 2008-08-15 | 2016-09-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748182A (en) * | 1986-03-05 | 1988-05-31 | Merrell Dow Pharmaceuticals Inc. | Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents |
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| US5300523A (en) * | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
| DE4138756A1 (de) * | 1991-11-26 | 1993-05-27 | Troponwerke Gmbh & Co Kg | Kombination mit neuroprotektiver wirkung |
-
1995
- 1995-11-22 DE DE19543478A patent/DE19543478A1/de not_active Withdrawn
-
1996
- 1996-10-30 AR ARP960104981A patent/AR004961A1/es unknown
- 1996-11-11 EP EP96118043A patent/EP0775704B1/de not_active Expired - Lifetime
- 1996-11-11 DE DE59607040T patent/DE59607040D1/de not_active Expired - Fee Related
- 1996-11-11 DK DK96118043T patent/DK0775704T3/da active
- 1996-11-11 PT PT96118043T patent/PT775704E/pt unknown
- 1996-11-11 AT AT96118043T patent/ATE201872T1/de not_active IP Right Cessation
- 1996-11-11 ES ES96118043T patent/ES2159342T3/es not_active Expired - Lifetime
- 1996-11-11 SI SI9630292T patent/SI0775704T1/xx unknown
- 1996-11-14 AU AU71772/96A patent/AU712922B2/en not_active Ceased
- 1996-11-18 JP JP8322212A patent/JPH09143180A/ja not_active Withdrawn
- 1996-11-19 US US08/752,348 patent/US5830908A/en not_active Expired - Fee Related
- 1996-11-19 NZ NZ299780A patent/NZ299780A/en unknown
- 1996-11-19 IL IL11964796A patent/IL119647A/xx not_active IP Right Cessation
- 1996-11-19 CA CA002190700A patent/CA2190700A1/en not_active Abandoned
- 1996-11-20 SG SG1996011319A patent/SG44989A1/en unknown
- 1996-11-20 PL PL96317090A patent/PL317090A1/xx unknown
- 1996-11-20 TW TW085114226A patent/TW449595B/zh not_active IP Right Cessation
- 1996-11-21 MX MX9605741A patent/MX9605741A/es unknown
- 1996-11-21 NO NO964950A patent/NO307340B1/no not_active IP Right Cessation
- 1996-11-21 BR BR9605646A patent/BR9605646A/pt unknown
- 1996-11-21 CZ CZ19963428A patent/CZ289730B6/cs not_active IP Right Cessation
- 1996-11-21 SK SK1500-96A patent/SK150096A3/sk unknown
- 1996-11-21 MY MYPI96004849A patent/MY132473A/en unknown
- 1996-11-21 ZA ZA969753A patent/ZA969753B/xx unknown
- 1996-11-21 EE EE9600183A patent/EE9600183A/xx unknown
- 1996-11-21 KR KR1019960056088A patent/KR970027079A/ko not_active Ceased
- 1996-11-21 UA UA96114365A patent/UA45338C2/uk unknown
- 1996-11-22 CN CN96114587A patent/CN1086703C/zh not_active Expired - Fee Related
- 1996-11-22 TR TR96/00930A patent/TR199600930A2/xx unknown
- 1996-11-22 RU RU96122395/04A patent/RU2181723C2/ru active
- 1996-11-22 HU HU9603237A patent/HUP9603237A3/hu unknown
-
2001
- 2001-08-31 GR GR20010401365T patent/GR3036505T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004961A1 (es) | Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el | |
| BG100635A (bg) | Заместени n-(индол-2-карбонил)-бета-аланинамиди и техни производни като антидиабетични средства | |
| ATE206611T1 (de) | Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung | |
| BR9908545A (pt) | Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica | |
| AP2000001860A0 (en) | Hypolipidemic benzothiazepine compounds. | |
| PT750618E (pt) | Derivados de oxazolidinona e composicoes farmaceuticas que os contem | |
| NO972261L (no) | Hypolipidemiske benzodiazepiner | |
| HN1998000074A (es) | Derivados de macrolidos c-4 sustituidos | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| PT101725A (pt) | Processo para a preparacao de um composto de diarilo anti-aterosclerotico e de composicoes farmaceuticas que o contem | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| FI972434A0 (fi) | Lamotrigiiniä sisältävä farmaseuttinen koostumus | |
| BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto | |
| NO965444L (no) | Triterpen-derivat samt medikamentell sammensetning omfattende dette | |
| ES2154830T3 (es) | Derivados de 2-aminolactama n-(4-bencilo sustituida). | |
| DE60225143D1 (de) | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes | |
| HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| DK0823909T3 (da) | Hidtil ukendte heterocykliske forbindelser | |
| HUP0004900A2 (hu) | Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények | |
| BR9610175A (pt) | Composto processo de preparação do composto composição farmacêutica e utilização do composto | |
| BR9306870A (pt) | Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol | |
| NO985974L (no) | Piperidineddiksyrederivater og deres anvendelse ved behandling av trombose-sykdommer | |
| ES2137665T3 (es) | Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos. | |
| BR0010338A (pt) | Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto | |
| BR0109252A (pt) | Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição |